Framing value

The American Society of Clinical Oncology's new cancer drug value framework was not intended as a tool for negotiating drug prices or reimbursement rates, but at least two payers are evaluating whether and how the tool could be used to inform coverage decisions.

ASCO published a draft of the tool in the Journal of Clinical Oncology on June 22. The framework was developed by a task force that included more than a dozen practicing oncologists, plus one representative each for patients, payers and industry...